KRMD

KORU Medical Systems, Inc. (KRMD) - 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2025. KORU Medical Systems, Inc. develops, manufactures, and commercializes large volume subcutaneous infusion solutions, primarily for the delivery of immunoglobulin to treat Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The company operates as a single segment with revenue streams from domestic core, international core, and pharma services/clinical trials.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 20.9% in Q2 2025 and 19.3% YTD compared to the prior year. Growth was driven by a 15.3% increase in domestic core revenue and a 33.9% increase in international core revenue. Pharma services and clinical trials revenue grew 42.1% in Q2.
• Profitability Improvement: Net loss narrowed significantly, decreasing 79.1% in Q2 and 53.1% YTD. This was primarily due to a $1.0 million increase in gross profit, partially offset by a slight increase in operating expenses.
• Margin Compression: Gross margin decreased slightly to 63.5% in Q2 (from 65.0% prior year) and 63.1% YTD (from 63.6% prior year). Management attributes this to a one-time favorable inventory valuation adjustment in the prior year and current year tariff-related charges.
• Expense Management: Operating expenses increased 1.7% in Q2 and 2.5% YTD. Selling, general, and administrative (SG&A) expenses rose due to recruiting costs for the Chief Commercial Officer role, while R&D expenses decreased YTD due to lower outsourced project spend.
• Liquidity: Cash balances decreased by $1.53 million YTD, primarily due to net operating losses, inventory build-up ($1.14 million increase), and capital expenditures ($0.47 million).

Outlook, Risks, and Management Commentary

• Guidance: The filing does not provide specific numerical financial guidance for the full year 2025. Management expects cash on hand and operating cash flows to be sufficient for at least the next twelve months.
• Tariff Impact: The company incurred $0.1 million in tariff-related charges in Q2 2025. Management expects these charges to have a gross margin impact of less than 100 basis points on an annualized basis.
• Capital Resources: The company has a $5 million revolving credit facility and a $5 million term loan facility, both currently undrawn. The maturity of the revolving facility was extended to December 31, 2026.
• Risks: Key risks include dependence on the subcutaneous immunoglobulin (SCIg) market, regulatory compliance (FDA), reimbursement risks, and the potential need for additional financing if growth accelerates faster than anticipated.
• Subsequent Events: A new commercial insurance premium finance agreement was renewed in July 2025 for $406,751.

Investor Verification Checklist

• Verify the sustainability of the 33.9% international revenue growth and the specific markets driving this expansion.
• Monitor the impact of tariffs on gross margins to ensure the impact remains under the projected 100 bps.
• Assess the timeline for the Chief Commercial Officer hire and its impact on future SG&A expenses and sales execution.
• Review the inventory build-up ($1.14 million increase YTD) to ensure it aligns with demand forecasts and does not lead to future write-downs.
• Confirm the status of the $10 million credit facility and any covenants that may be triggered by continued net losses.